Vir Biotechnology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Net Income	-615.06	515.84	528.58	-298.67	-174.68	-115.88	-69.85
Depreciation & Amortization	27.11	15.49	11.98	8.81	4.52	2.76	0.43
Share-Based Compensation	111.32	102.08	83.78	27.6	8.72	5.05	4.78
Other Operating Activities	-302.15	1,030	-671.94	71.31	31.82	13.98	-1.74
Operating Cash Flow	-778.79	1,663	-47.59	-190.94	-129.63	-94.1	-66.38
Capital Expenditures	-21.57	-68.01	-21.82	-6.55	-8.94	-8.17	-2.74
Acquisitions	0	0	0	0	0	-1.74	-27.25
Change in Investments	186.2	-1,125.46	-119	-3.49	-247.22	-50.53	0
Other Investing Activities	-	-	-	0.18	-	-	-
Investing Cash Flow	164.63	-1,193.46	-140.81	-9.86	-256.16	-60.44	-29.99
Share Issuance / Repurchase	7.77	36.22	100.59	533.97	127.54	0.58	0
Debt Issued / Paid	-0.29	-0.26	-0.26	-0.25	4.37	0	0
Other Financing Activities	-	-1.2	-	-4.25	317.34	24.39	271.18
Financing Cash Flow	7.48	34.76	100.33	529.47	449.24	24.98	271.18
Net Cash Flow	-606.68	504.55	-88.07	328.67	63.45	-129.56	174.81
Free Cash Flow	-800.36	1,595	-69.41	-197.49	-138.57	-102.26	-69.12
Free Cash Flow Margin	-928.71%	98.73%	-6.34%	-258.60%	-1712.67%	-958.60%	-2552.55%
Free Cash Flow Per Share	-5.97	12.03	-0.53	-1.66	-4.57	-13.34	-32.12

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).